banner
June 2017
David Craig, PharmD | Editor

Advocacy

advocacyFederal Pain Research Strategy (FPRS): Draft Research Priorities

On June 1, immediately following the 12th Annual Pain Consortium Symposium, a forum was convened in which a representative of each of the FPRS work groups presented their top recommendations. There was a substantive discussion period which allowed feedback to each of the groups and to cochairs Drs. Alan Basbaum and Linda Porter.

The draft is available on the IPRCC website and was open for public comment May 25–June 6. Following public comment review, the strategy will be modified as needed and re-released in final form.

The 12th Annual NIH Pain Consortium Symposium

On May 31–June 1, 2017, the NIH Pain Consortium held the 12th Annual NIH Pain Consortium Symposium: Multidisciplinary Strategies for the Management of Pain. The 2017 symposium highlighted advances in pain research on prevention of chronic pain and moving toward multidisciplinary pain care. The archived videocast is available here.

Draft Revisions to the U.S. Food & Drug Administration (FDA) Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioids

On May 9–10, the FDA held a 2-day public workshop to obtain input on issues and challenges associated with Federal efforts to train prescribers on pain management and the safe use of opioids. There appeared to be a general consensus in favor of mandatory education but there was no agreement on how that could be accomplished. It was noted that incorporating it into Drug Enforcement Agency registration would require a change in the law.

Reminder—all are encouraged to submit their comments by July 10.

From the Executive Office of the President—Federal Register Notice of Meeting

As noted in the Federal Register, the Office of National Drug Control Policy is convening a public meeting of the Notification of a Public Meeting of the President’s Commission on Combating Drug Addiction and the Opioid Crisis (Commission) to work on drug issues and the opioid crisis per Executive Order 13784.

The first meeting consisted of statements to the Commission from invited nonprofit organizations regarding drug issues followed by a discussion of the issues raised. The first Commission meeting was held on Friday, June 16, 2017, from 12:30 pm until approximately 2:30 pm (Eastern Time). It was webcast, and written statements to the Commission are welcome. To date, a list of the invited organizations is unknown.

Dr. Collins and National Institute on Drug Abuse (NIDA) Director Dr. Volkow Coauthor a New England Journal of Medicine (NEJM) Special Report on the Role of Science in Addressing the Opioid Crisis

In a coauthored NEJM special report, Dr. Collins and NIDA Director Dr. Nora Volkow outline a new public-private partnership initiative to address the opioid crisis. This new initiative will focus on three scientific areas: overdose-reversal and prevention interventions, new medications to treat opioid addiction, and nonaddictive interventions for chronic pain. N Engl J Med. Online: May 31, 2017.